in ,

Ricin Vaccine Featured at Rare Diseases and Orphan Products Summit

Credit: Shutterstock
Ricin Toxin Structure Model
Credit: Shutterstock

Soligenix, Inc. will present preclinical efficacy findings from its RiVax™ ricin toxin vaccine program at the National Organization for Rare Disorders’ (NORD’s) Rare Diseases and Orphan Products Breakthrough Summit on October 17-18, 2016 in Arlington, VA.

RiVax is the company’s proprietary vaccine candidate for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin.  When formulated with Soligenix’s proprietary heat-stabilization ThermoVax® technology, RiVax™ has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models.

The presented results, titled “Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine,” will be available for viewing throughout the conference and will address preclinical efficacy findings.

More details about the conference can be found at

Yersinia Pestis Commonly Known as the Plague

DoD to Study Omadacycline as Countermeasure for Plague, Anthrax

Health Security Headlines for Influenza and Malaria

Biodefense Headlines – October 16, 2016